Sign In
Buy AVVIY
Aviva Earnings Calls
| Release date | Mar 05, 2026 |
| EPS estimate | $0.86 |
| EPS actual | $0.732 |
| EPS Surprise | -14.49% |
| Revenue estimate | 39.2B |
| Revenue actual | 39.07B |
| Revenue Surprise | -0.331% |
| Release date | Aug 12, 2025 |
| EPS estimate | $0.716 |
| EPS actual | $0.706 |
| EPS Surprise | -1.40% |
| Revenue estimate | 34.873B |
| Revenue actual | 16.851B |
| Revenue Surprise | -51.68% |
| Release date | May 16, 2025 |
| EPS estimate | - |
| EPS actual | - |
| Revenue estimate | - |
| Revenue actual | - |
| Release date | Feb 27, 2025 |
| EPS estimate | $0.610 |
| EPS actual | $0.0316 |
| EPS Surprise | -94.82% |
| Revenue estimate | 34.406B |
| Revenue actual | 26.169B |
| Revenue Surprise | -23.94% |
Last 4 Quarters for Aviva
Below you can see how AVVIY performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 27, 2025 |
| Price on release | $14.02 |
| EPS estimate | $0.610 |
| EPS actual | $0.0316 |
| EPS surprise | -94.82% |
| Date | Price |
|---|---|
| Feb 21, 2025 | $12.73 |
| Feb 24, 2025 | $12.86 |
| Feb 25, 2025 | $13.12 |
| Feb 26, 2025 | $13.44 |
| Feb 27, 2025 | $14.02 |
| Feb 28, 2025 | $13.92 |
| Mar 03, 2025 | $13.84 |
| Mar 04, 2025 | $13.87 |
| Mar 05, 2025 | $14.25 |
| 4 days before | 10.13% |
| 4 days after | 1.64% |
| On release day | -0.713% |
| Change in period | 11.94% |
| Release date | May 16, 2025 |
| Price on release | $15.67 |
| EPS estimate | - |
| EPS actual | - |
| Date | Price |
|---|---|
| May 12, 2025 | $15.37 |
| May 13, 2025 | $15.48 |
| May 14, 2025 | $15.40 |
| May 15, 2025 | $15.78 |
| May 16, 2025 | $15.67 |
| May 19, 2025 | $15.92 |
| May 20, 2025 | $16.31 |
| May 21, 2025 | $16.32 |
| May 22, 2025 | $16.50 |
| 4 days before | 1.99% |
| 4 days after | 5.30% |
| On release day | 1.60% |
| Change in period | 7.39% |
| Release date | Aug 12, 2025 |
| Price on release | $18.07 |
| EPS estimate | $0.716 |
| EPS actual | $0.706 |
| EPS surprise | -1.40% |
| Date | Price |
|---|---|
| Aug 06, 2025 | $17.78 |
| Aug 07, 2025 | $17.80 |
| Aug 08, 2025 | $17.85 |
| Aug 11, 2025 | $17.93 |
| Aug 12, 2025 | $18.07 |
| Aug 13, 2025 | $18.23 |
| Aug 14, 2025 | $18.67 |
| Aug 15, 2025 | $18.46 |
| Aug 18, 2025 | $18.14 |
| 4 days before | 1.63% |
| 4 days after | 0.387% |
| On release day | 1.05% |
| Change in period | 2.02% |
| Release date | Mar 05, 2026 |
| Price on release | $17.39 |
| EPS estimate | $0.86 |
| EPS actual | $0.732 |
| EPS surprise | -14.49% |
| Date | Price |
|---|---|
| Feb 27, 2026 | $18.48 |
| Mar 02, 2026 | $18.44 |
| Mar 03, 2026 | $17.68 |
| Mar 04, 2026 | $18.05 |
| Mar 05, 2026 | $17.39 |
| Mar 06, 2026 | $17.05 |
| Mar 09, 2026 | $16.82 |
| Mar 10, 2026 | $16.88 |
| Mar 11, 2026 | $17.04 |
| 4 days before | -5.90% |
| 4 days after | -2.01% |
| On release day | -1.96% |
| Change in period | -7.79% |
Aviva Earnings Call Transcript Summary of Q4 2025
Aviva reported a strong 2025, with operating profit up 25% to £2.2bn, operating EPS of 56p and an IFRS return on equity of 17.5%. The results include a 6-month contribution from Direct Line. Management says it has met its 2026 targets a year early and has raised its 3-year ambitions (new targets include Direct Line). Key capital and shareholder actions: a final dividend of 26.2p (total 39.3p, +10% y/y) and a resumed share buyback programme of £350m. General Insurance performed well (group combined ratio 94.6%; UK & Ireland COR 93.9%), with GI premiums up materially and management aiming for <94% COR in 2026 (subject to normal weather). Wealth is a strategic growth area: assets >£230bn, record net flows (~£11bn), Workplace AUM £153bn, and a £280m Wealth profit ambition for 2027; longer-term Wealth opportunity remains large given market growth and regulatory tailwinds. Retirement wrote £4.6bn of bulk annuities at mid‑teens IRRs and Aviva Investors originated £3.5bn of real assets to support this. Direct Line integration is progressing: cost-synergy target uplift to £225m (first £50m delivered in H2 2025; £175m to follow over next 3 years) and asset transfers to Aviva Investors. AI is a company priority: Aviva cites ~£100m already saved through claims transformation and announced a partnership with OpenAI; plans to pilot an AI-enabled, voice‑enabled claims agent later in the year. Capital: solvency at 180% (top end of range) supported by £2.3bn own funds generation; management expects to deliver at least c.£350m (≈7 solvency points) of Direct Line synergies by year end and ~20 solvency points operating capital generation in 2027. Risks/considerations: GI remains cyclical and highly competitive; management stresses pricing discipline and the potential for weather, large losses or competitive moves to affect near-term COR. Overall tone: confident — management highlights diversification, scale, proprietary data, and AI as competitive advantages and reiterates progressive capital returns alongside investment for growth.
